A Phase I/II Study of Etanercept and Rituximab in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Rituximab has modest activity in relapsed Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) but is associated with TNF-α release that can cause CLL proliferation and inhibit apoptosis. We examined whether disruption of TNF-α by etanercept improves response to rituximab in CLL. Eligible p...

Descripción completa

Detalles Bibliográficos
Autores principales: Woyach, Jennifer A, Lin, Thomas S, Lucas, Margaret S, Heerema, Nyla, Moran, Mollie E., Cheney, Carolyn, Lucas, David M., Wei, Lai, Caligiuri, Michael A., Byrd, John C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2009
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099250/
https://www.ncbi.nlm.nih.gov/pubmed/19225537
http://dx.doi.org/10.1038/leu.2008.385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099250/
https://www.ncbi.nlm.nih.gov/pubmed/19225537
http://dx.doi.org/10.1038/leu.2008.385

Ejemplares similares